Protocol Ledger

NCT07499674 · Phase III · RECRUITING

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Interventional Phase III clinical trial protocol NCT07499674 sponsored by Vergent Bioscience in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-31 Enrollment: 132 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07499674
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)132 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07499674
Protocol FieldVerified Registry Value
NCT IdentifierNCT07499674
Consolidated Lead SponsorVergent Bioscience
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment132 participants (ESTIMATED)
Registered Start Date2026-03-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI